Compare abrdn Income Credit Strategies Fund (ACP) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Tilray Brands Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Tilray Brands Inc trades at $4.38 (market cap $532.10M). The key difference: abrdn Income Credit Strategies Fund is the larger of the two by market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| ACP | TLRY | |
|---|---|---|
Market Cap | $656.21M | $532.10M |
Sector | Financials | Health |
52-Week High | $5.98 | $21.00 |
52-Week Low | $5.01 | $4.31 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $629.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
TLRY trades at $4.38, down 5.19% today, reflecting ongoing investor concerns about profitability despite revenue growth to $821 million in 2025. The stock shows bearish technical signals with key support at $4 and resistance at $5. Recent acquisitions and medical cannabis expansion provide growth avenues, but negative net income margins and cash flow challenges persist. Analyst consensus remains cautious with 65% hold ratings.
TLRY presents a high-risk opportunity with potential upside from strategic acquisitions and market expansion, but significant challenges include persistent losses, negative cash flow, and regulatory uncertainties. The stock's low P/S (0.54) and P/B (0.35) ratios suggest undervaluation, but profitability remains the critical hurdle for sustainable growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
